What one share of Palisade Bio holds
We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (“PDE4”) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”) and Crohn’s disease (“CD”).
Palisade Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.20 |
| Cash and investments | $0.72 |
| Book value | $0.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$2,546 | $0.00 | −$1,185 | — | $387.93 |
| 2022 | $0.00 | −$247.89 | $0.17 | −$227.82 | — | — |
| 2023 | $0.55 | −$27.01 | $0.01 | −$24.42 | — | $18.30 |
| 2024 | $0.00 | −$10.19 | $0.00 | −$8.61 | — | $2.71 |
| 2025 | $0.00 | −$0.30 | — | — | — | $0.81 |
Common questions about Palisade Bio
How much does one share of Palisade Bio earn?
Over the last 12 months, Palisade Bio lost $0.20 for each share.
Does Palisade Bio pay a dividend?
Palisade Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Palisade Bio’s book value per share?
Palisade Bio’s book value is $0.70 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Palisade Bio have?
Each share of Palisade Bio has $0.72 of cash and investments, as of June 30, 2026.
Has Palisade Bio bought back shares?
Palisade Bio’s share count rose about 446550% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.